BI35: A Case of Dupilumab-Induced Scalp Psoriasis and Review of the Literature

Dupilumab, a monoclonal antibody used to treat moderate-to-severe atopic dermatitis (AD), has been associated with the onset of psoriasis in some patients. This case study describes a 32-year-old man with a history of AD who developed scalp psoriasis and hair loss after 4 months of dupilumab treatment, despite having no personal or family history of psoriasis. The psoriasis resolved after discontinuing dupilumab and starting topical steroids. The literature reports 47 cases of dupilumab-associated psoriasis, with a mean onset time of 4.3 months. The proposed mechanism involves a shift in immune response due to the blockade of the IL-4/IL-13 pathway, potentially leading to psoriatic lesions. Dermatologists should consider psoriasis as a possible side effect of dupilumab.